【11/19 12:00-】BlockbusterTOKYO 2020 第7回 研修プログラム「バイオテックにおけるビジネスモデルの構築」 -Business model developing for Biotech startups
Seminar program in Blockbuster TOKYO 2020
Blockbuster TOKYOは東京都が主催し、Beyond Next Ventures株式会社が運営する創薬・医療系ベンチャー育成支援プログラムです。今回は、バイオスタートアップのビジネスモデルについて、成功を収めた3名の起業家をお招きして考察していきます。
Beyond Next Ventures, Inc. operates Tokyo Metropolitan Government's "Blockbuster TOKYO" which is an acceleration program for pharmaceutical and medical startup. This seminer, we invited 3 successfule entrepreneurs to discuss about business model in bio-tech startups.
Startups must consider and develop their business models in addition to their technologies. History shows that these are equally, if not more important, to get right. Founders and startup executives have the freedom (and challenge) of experimenting with business models. Great outcomes occur when technology, business model and team are properly aligned. Blockbuster Tokyo is pleased to be joined by three seasoned entrepreneurs for a fireside chat where they will share their experiences developing and executing business models across a range of successful bioventures.
November 19, 2020 (Thu) 12: 00-13: 30 (JST)
【オンラインリンク/ Link for the online seminar】
＊We will send Link for the seminar via e-mail by the day before . You can't access that from this event page.
・Beyond Next Ventures からのご挨拶 / Introduction from Beyond Next Ventures
・バイオテックにおけるビジネスモデルの構築/ Business model developing for biotech startups
・2020年度の活動紹介/ Introduction of programs for Blockbuster TOKYO 2020
・製薬・医療領域に関連するスタートアップ、またアカデミック分野にいる方を主な対象としています。/ Audience: early stage startups, academia
CEO & Founder, B-Bridge International, CEO & Founder Silicon Valley Japan College
Experienced Executive with a demonstrated history of working in the biotechnology industry. Skilled in Products Management, Technology Transfer, and Commercialization. Strong entrepreneurship professional. Experienced from Toyobo and CLONTECH Laboratories.
Harold E. Van Wart, Ph.D.
Advisor, Stanford SPARK translational medicine program
Dr. Van Wart served as Chief Executive Officer of CymaBay Therapeutics and was a member of the Board of Directors from January 2003 until his retirement in April 2017. He was also President from April 2001 to April 2017. He served as Chief Operating Officer of the predecessor company Metabolex from December 2002 to January 2003 and Senior Vice President, Research and Development from October 2000 to December 2002. From 1999 to 2000, Dr. Van Wart was Vice President and Therapy Head for arthritis and fibrotic diseases at Roche Bioscience, a biopharmaceutical company. From 1992 to 1999, he was Vice President and Director of the institute of biochemistry and cell biology at Syntex Corporation, a biopharmaceutical company acquired by Roche Bioscience in 1994. From 1978 to 1992, Dr. Van Wart served on the chemistry faculty of Florida State University. He was also a Director of Conatus Pharmaceuticals, Inc. from 2007 to 2019. He served on the Emerging Companies and Health Section Governing Boards of the Biotechnology Industry Organization as well as on its Board of Directors from 2004 to 2017. He was Chair of BayBio in 2013 and helped found the California Life Sciences Association in 2014 and served as Chair in 2016. He is an Advisor to the Stanford SPARK translational medicine program. Dr. Van Wart holds a Ph.D. from Cornell in Biophysical Chemistry.
David S. Johnson, Ph.D., MBA
Chief Executive Officer and Co-Founder, GigaGen
Dr. Johnson is an inventor, entrepreneur, and expert in single-cell immunology, with a track record of bringing new medical technologies to market. Since founding GigaGen, Dr. Johnson has raised approximately $52 million in partnerships with established pharmaceutical companies, including Grifols, Novartis, and Merck. He has also served as principal investigator for 16 grants totaling over $10 million from the National Science Foundation, National Cancer Institute and National Institute of Allergy and Infectious Diseases, including seven Phase 2 projects. Prior to GigaGen, Dr. Johnson was a founding member and chief operating officer of Natera (NASDAQ: NTRA), a reproductive molecular diagnostics firm. At Natera, Dr. Johnson was responsible for all clinical operations, laboratory research, clinical studies and clinical product development. Previously, he served as a project director at the Stanford Human Genome Center. Dr. Johnson holds a B.S. in Biology from Duke University, a Ph.D. in Genetics from Stanford University and an MBA from the Haas School of Business at the University of California, Berkeley. Dr. Johnson is widely published in journals such as Science, Nature Methods, Nature Biotechnology, Blood and mAbs.
Mayu Moroshima, Ph. D.
Executive Officer, Beyond Next Ventures Inc.
After working with large pharmaceutical and medical companies as a consultant at McKinsey & Company, Mayu Morishima joined BNV to work more closely with startup companies and support raw innovation in Japan. In addition to leading BNV’s life science and biotech investments, Mayu is in charge of BNV’s global expansion and Blockbuster TOKYO program as one of its core management members. Mayu’s goal is to transform innovations in academia, especially in Japan, into actual products that improve people’s lives and society. Mayu’s research experience includes characterization of the mechanism of piRNAs, those have been linked to gene silencing of retrotransposons and other genetic elements while undergoing molecular biology training as a graduate student at Kyoto University and the University of Tokyo. Mayu also studied drug-resistant tuberculosis strains in a genotyping project at the KwaZulu-Natal Research Institute for TB and HIV (K-RITH) in South Africa.
Caleb B. Bell III, Ph.D.
Beyond Next ventures Inc.
Caleb is a passionate entrepreneur, well-published scientist and enthusiastic investor. He received a business training and PhD in Biophysical Chemistry from Stanford University and spun a Cell Therapy company out of Stanford. Through his Academic training and businesses, Caleb has had many interactions with Japan and is focused on building trans Pacific bridges to support commercialization of life science and biotech innovations and innovators.
東京都から委託を受けたBeyond Next Ventures(株)が、創薬・医療系ベンチャーやベンチャーの起業を目指す研究者等を対象に実施 する育成支援プログラムです。
Beyond Next Ventures, Inc. operates Tokyo Metropolitan Government's "Blockbuster TOKYO" which is an acceleration program for pharmaceutical and medical startup. The program aims to accelerate foundation and growth of pharmaceutical and medical startups by providing various supports.
【Beyond Next Ventures】
Beyond Next Ventures(株)は、2014年8月に創業した、医療機器、デジタルヘルスや再生医療等のライフサイエンス分野を中心に革新的な技術を有する大学発・技術系ベンチャーへのインキュベーション投資に特化した独立系ベンチャーキャピタルです。
また、2019年からは、日本橋にてシェア型のウェットラボ、「Beyond BioLAB TOKYO」や、技術シーズと共同創業者をマッチングする「Co-founders」を運営しています。
Beyond Next Ventures is a venture capital that supports the creation of startups based on technology from universities. Established in 2014, we invest in innovative start-ups such as life sciences, healthcare, robots, devices, etc. Our program "BRAVE" is the largest accelerating platform in Japan, targeting university areas. And we run "Beyond BioLAB TOKYO", which is the only shared-laboratory in Tokyo.
Blockbuster TOKYO お問い合わせ先
Blockbuster TOKYO 運営事務局 (Beyond Next Ventures株式会社内)
E-mail : email@example.com
web : https://www.blockbuster.tokyo
- イベント詳細情報を更新しました。 Diff#825466 2020-11-18 02:21:36